Evaluating differences in melanoma patients referred for germline testing: a retrospective cohort study
Archives of Dermatological Research
Sarah Amjad, Jacob Breinholt, Micah Starghill, Andy Ho, Michael A. Golafshar, Cassidy Carraway, Aaron R. Mangold, Collin M. Costello
Excerpt
Of patients tested for a familial germline mutation, only 10–15% of patients are found to have a pathogenic germline variant (PGV) []. Previous studies have demonstrated that PGV-negative patients exhibit distinct clinical and pathological features to PGV-positive patients, including decreased survival, less-significant family history, and later onset of melanoma [, ]. We sought to further identify differences between PGV-positive and PGV-negative patients for whom clinicians had ordered germline testing.
This was a retrospective, multicenter, single-institution cohort study. Inclusion criteria included a melanoma diagnosis and germline test performed. See Online Resource 1 for supplementary methods.
Related publications